BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30587457)

  • 1. De novo malignancy in heart transplant recipients: A single center experience in Japan.
    Kimura Y; Yanase M; Mochizuki H; Iwasaki K; Toda K; Matsuda S; Takenaka H; Kumai Y; Kuroda K; Nakajima S; Watanabe T; Ikura MM; Wada K; Matsumoto Y; Seguchi O; Fukushima S; Fujita T; Kobayashi J; Fukushima N
    J Cardiol; 2019 Mar; 73(3):255-261. PubMed ID: 30587457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temporal Trends of De Novo Malignancy Development After Heart Transplantation.
    Youn JC; Stehlik J; Wilk AR; Cherikh W; Kim IC; Park GH; Lund LH; Eisen HJ; Kim DY; Lee SK; Choi SW; Han S; Ryu KH; Kang SM; Kobashigawa JA
    J Am Coll Cardiol; 2018 Jan; 71(1):40-49. PubMed ID: 29301626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De novo malignancy after lung transplantation in Japan.
    Miyazaki T; Oto T; Okumura M; Date H; Shiraishi T; Okada Y; Chida M; Kondo T; Nagayasu T
    Gen Thorac Cardiovasc Surg; 2016 Sep; 64(9):543-8. PubMed ID: 27270709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between infectious event and de novo malignancy after heart transplantation.
    Bujo C; Amiya E; Hatano M; Tsuji M; Maki H; Ishida J; Ishii S; Narita K; Endo M; Ando M; Shimada S; Kinoshita O; Ono M; Komuro I
    Heart Vessels; 2021 Apr; 36(4):499-508. PubMed ID: 33140148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. National survey of de novo malignancy after solid organ transplantation in Japan.
    Miyazaki T; Sato S; Kondo T; Kusaka M; Gotoh M; Saiki Y; Ono M; Kokudo N; Enosawa S; Satoh S; Soeda E; Furukawa H; Kobayashi E; Nagayasu T
    Surg Today; 2018 Jun; 48(6):618-624. PubMed ID: 29380136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunosuppression, Race, and Donor-Related Risk Factors Affect De novo Cancer Incidence Across Solid Organ Transplant Recipients.
    Bhat M; Mara K; Dierkhising R; Watt KDS
    Mayo Clin Proc; 2018 Sep; 93(9):1236-1246. PubMed ID: 30064826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De Novo Anti-HLA Antibodies After Heart Transplantation Are Associated With Adverse Events in the Long-term Follow-up of Cardiac Transplant Recipients.
    Solé-González E; Mirabet S; Brossa V; López-López L; Rivas-Lasarte M; Capellades-Olivella H; Ginel-Iglesias AJ; Martorell-Pons J; Roig E
    Transplant Proc; 2016 Nov; 48(9):3030-3032. PubMed ID: 27932139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High rates of de novo malignancy compromise post-heart transplantation survival.
    Giuliano K; Canner JK; Etchill E; Suarez-Pierre A; Choi CW; Higgins RSD; Hsu S; Sharma K; Kilic A
    J Card Surg; 2021 Apr; 36(4):1401-1410. PubMed ID: 33567114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency and spectrum of metachronous malignancies in heart transplant recipients: a 11-year-experience at a German heart center.
    Strecker T; Rösch J; Weyand M; Agaimy A
    Int J Clin Exp Pathol; 2013; 6(3):411-20. PubMed ID: 23412350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and outcomes of heart transplant recipients with a pretransplant history of malignancy.
    Youn JC; Kim D; Kim KA; Kim JJ; Kim IC; Lee HS; Choi JO; Jeon ES; Nishihara K; Kransdorf EP; Chang DH; Kittleson MM; Patel JK; Ramzy D; Esmailian F; Kobashigawa JA
    Am J Transplant; 2022 Dec; 22(12):2942-2950. PubMed ID: 36050598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De Novo Malignancy After Heart, Kidney, and Liver Transplant: A Nationwide Study in Taiwan.
    Yeh CC; Khan A; Muo CH; Yang HR; Li PC; Chang CH; Chen TL; Jeng LB; Liao CC
    Exp Clin Transplant; 2020 Apr; 18(2):224-233. PubMed ID: 32133940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De novo head and neck cancer arising in solid organ transplantation recipients: The Asan Medical Center experience.
    Park MJ; Roh JL; Choi SH; Nam SY; Kim SY; Lee YS
    Auris Nasus Larynx; 2018 Aug; 45(4):838-845. PubMed ID: 29150348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of recipient age and causes of heart transplant mortality: Implications for personalization of post-transplant management-An analysis of the International Society for Heart and Lung Transplantation Registry.
    Wever-Pinzon O; Edwards LB; Taylor DO; Kfoury AG; Drakos SG; Selzman CH; Fang JC; Lund LH; Stehlik J
    J Heart Lung Transplant; 2017 Apr; 36(4):407-417. PubMed ID: 27686602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in invasive disease due to Candida species following heart and lung transplantation.
    Schaenman JM; Rosso F; Austin JM; Baron EJ; Gamberg P; Miller J; Oyer PE; Robbins RC; Montoya JG
    Transpl Infect Dis; 2009 Apr; 11(2):112-21. PubMed ID: 19254327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low incidence of malignancy in heart-transplant recipients in Taiwan: an update and comparison with kidney-transplant recipients.
    Hsu RB; Chang CI; Tsai MK; Lee PH; Chou NK; Chi NH; Wang SS; Chu SH
    Eur J Cardiothorac Surg; 2010 May; 37(5):1117-21. PubMed ID: 20045346
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Manzia TM; Angelico R; Gazia C; Lenci I; Milana M; Ademoyero OT; Pedini D; Toti L; Spada M; Tisone G; Baiocchi L
    World J Gastroenterol; 2019 Sep; 25(35):5356-5375. PubMed ID: 31558879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-transplant malignancy in liver transplantation: a single center experience.
    Hsiao CY; Lee PH; Ho CM; Wu YM; Ho MC; Hu RH
    Medicine (Baltimore); 2014 Dec; 93(28):e310. PubMed ID: 25526480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De novo DQ donor-specific antibodies are associated with worse outcomes compared to non-DQ de novo donor-specific antibodies following heart transplantation.
    Cole RT; Gandhi J; Bray RA; Gebel HM; Morris A; McCue A; Yin M; Laskar SR; Book W; Jokhadar M; Smith A; Nguyen D; Vega JD; Gupta D
    Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28181305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. De Novo Malignancies After Transplantation: Risk and Surveillance Strategies.
    Doycheva I; Amer S; Watt KD
    Med Clin North Am; 2016 May; 100(3):551-67. PubMed ID: 27095645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of post-transplant malignancy among 674 solid-organ-transplant recipients at a single center.
    Mihalov ML; Gattuso P; Abraham K; Holmes EW; Reddy V
    Clin Transplant; 1996 Jun; 10(3):248-55. PubMed ID: 8826661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.